This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 450% and 7.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
by Sundeep Ganoria
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
by Zacks Equity Research
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar?
by Zacks Equity Research
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 17.14% and 14.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -100% and 0.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?
by Zacks Equity Research
Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -1,700% and 1.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help Kiniksa Pharmaceuticals (KNSA) Maintain Its Recent Price Strength
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 42.3% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kiniksa Pharmaceuticals (KNSA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks.com featured highlights include Kiniksa Pharmaceuticals, HNI, AudioEye, Balchem and The Gorman-Rupp
by Zacks Equity Research
Kiniksa Pharmaceuticals, HNI, AudioEye, Balchem and The Gorman-Rupp have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength in a Volatile Market
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are KNSA, HNI, AEYE, BCPC, GRC.
Best Momentum Stocks to Buy for August 1st
by Zacks Equity Research
CVNA, QCRH, and KNSA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 1, 2024.
New Strong Buy Stocks for August 1st
by Zacks Equity Research
NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.